Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(20)30074-7 ◽

2020 ◽

Vol 8 (5) ◽

pp. 392-406 ◽

Author(s):

Daisuke Yabe ◽

Jiro Nakamura ◽

Hideaki Kaneto ◽

Srikanth Deenadayalan ◽

Andrea Navarria ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Safety And Efficacy ◽

Download Full-text

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus:post hocsubgroup analyses according to body mass index in a 52-week open-label study

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1055250 ◽

2015 ◽

Vol 16 (11) ◽

pp. 1577-1591 ◽

Author(s):

Nobuya Inagaki ◽

Maki Goda ◽

Shoko Yokota ◽

Nobuko Maruyama ◽

Hiroaki Iijima

Keyword(s):

Type 2 Diabetes ◽

Body Mass Index ◽

Body Mass ◽

Japanese Patients ◽

Open Label Study ◽

Label Study ◽

Safety And Efficacy

Download Full-text

Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12693 ◽

2016 ◽

Vol 18 (9) ◽

pp. 925-929 ◽

Author(s):

K. Kaku ◽

K. Enya ◽

R. Nakaya ◽

T. Ohira ◽

R. Matsuno

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Safety And Efficacy ◽

Open Label Phase ◽

Phase Iii Study ◽

G Protein Coupled

Download Full-text

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes ( TIMES 2): a 52‐week open‐label, multicenter phase 3 trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14613 ◽

2021 ◽

Author(s):

Julie Dubourg ◽

Pascale Fouqueray ◽

Damien Quinslot ◽

Jean‐Marie Grouin ◽

Kohei Kaku

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Phase 3 ◽

Antidiabetic Agents ◽

Safety And Efficacy ◽

Multicenter Phase

Download Full-text

Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2018.1434145 ◽

2018 ◽

Vol 19 (4) ◽

pp. 327-336 ◽

Author(s):

Hiroshi Maegawa ◽

Kazuyuki Tobe ◽

Hiromi Tabuchi ◽

Ichiro Nakamura ◽

Satoshi Uno

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Safety And Efficacy ◽

Long Term Study ◽

Elderly Japanese ◽

Elderly Japanese Patients

Download Full-text

Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial

Internal Medicine ◽

10.2169/internalmedicine.3473-19 ◽

2020 ◽

Vol 59 (5) ◽

pp. 601-609 ◽

Author(s):

Masashi Tanaka ◽

Hajime Yamakage ◽

Takayuki Inoue ◽

Shinji Odori ◽

Toru Kusakabe ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Function ◽

Uric Acid ◽

Serum Uric Acid ◽

Controlled Trial ◽

Japanese Patients ◽

Beneficial Effects

Download Full-text

Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open‐label, active‐controlled study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13421 ◽

2018 ◽

Vol 20 (11) ◽

pp. 2675-2679 ◽

Author(s):

Yuya Tsurutani ◽

Kazuki Nakai ◽

Kosuke Inoue ◽

Kosuke Azuma ◽

Sei Mukai ◽

...

Keyword(s):

Type 2 Diabetes ◽

Comparative Study ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Variables

Download Full-text

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v3/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic

Download Full-text

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v2/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic

Download Full-text

Review for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v1/review1 ◽

2019 ◽

Author(s):

Graydon Meneilly

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Oral Antidiabetic

Download Full-text

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review5 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Fat Reduction ◽

Randomised Controlled Study ◽

Randomised Controlled

Download Full-text